Evidence map›Paper›PMID 41388239›Full record

ArticleThe journal of headache and pain2025

Persistence, switching, and healthcare use after initiating calcitonin gene-related peptide inhibitors: a real-world assessment.

Cristiano S Moura, Jason R Randall, Scott Klarenbach, Hassan Behlouli, Huong Luu, Farnaz Amoozegar, Jean-Luc Kaboré, Sasha Bernatsky

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cristiano S MouraCentre for Outcomes Research and Evaluation, The Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve Ouest, (3F.51) Montreal, Montreal, QC, H4A 3S5, Canada.
Jason R RandallReal World Evidence Unit, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Scott KlarenbachReal World Evidence Unit, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Hassan BehlouliCentre for Outcomes Research and Evaluation, The Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve Ouest, (3F.51) Montreal, Montreal, QC, H4A 3S5, Canada.
Huong LuuReal World Evidence Unit, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Farnaz AmoozegarDepartment of Clinical Neurosciences, Division of Neurology, Cumming School of Medicine, South Health Campus, University of Calgary, Calgary, Canada.
Jean-Luc KaboréInstitut National d'Excellence en Santé et en Services Sociaux (INESSS) du Québec, Montreal, Canada.
Sasha BernatskyCentre for Outcomes Research and Evaluation, The Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve Ouest, (3F.51) Montreal, Montreal, QC, H4A 3S5, Canada. sasha.bernatsky@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMigraine is a prevalent and disabling condition affecting one billion people worldwide. calcitonin gene-related peptide (CGRP) inhibitors have transformed migraine management. We describe real-world trends in CGRP inhibitor treatment, switching, discontinuation, and migraine-related health care use (including emergency department, ED, and ambulatory care visits).

methodsWe used the Merative™ MarketScan

resultsWe studied 148,100 adults with at least one CGRP inhibitor dispensation. CGRP inhibitor use increased over time, with newer agents being more commonly dispensed in recent years. Within the first year, 10.3% of individuals switched between CGRP inhibitors, and an additional 13.5% discontinued their first CGRP inhibitor without switching to another. Post-initiation, there was a 4.5% reduction in migraine-related medication use (95% confidence interval, CI: -4.9% to -4.0%, and 12.8% reduction in healthcare use (95% CI: -13.2% to -12.3%).

conclusionsCGRP inhibitors are increasingly used over time. About 10% switch between CGRP agents within the first year of initiation. There was reduction in other migraine-related medications and healthcare visits following CGRP initiation.

trial registrationN/A.

Indexed as

Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsDrug SubstitutionMigraine DisordersPatient Acceptance of Health CareAdultAgedFemaleHumansMaleMiddle AgedUnited StatesYoung AdultCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAdministrative dataCalcitonin gene-related peptide inhibitorsMigraineTreatment patterns

Identifiers

PMID41388239
PMCPMC12817865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.